Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Wolf A, Stratmann JA, Shaid S, Niklas N, Calleja A, Ubhi H, Munro R, Waldenberger D, Carroll R, Daumont MJ, Penrod JR, Lacoin L, Rohde G. Wolf A, et al. Among authors: waldenberger d. BMC Pulm Med. 2023 Jan 13;23(1):16. doi: 10.1186/s12890-022-02288-1. BMC Pulm Med. 2023. PMID: 36639770 Free PMC article.
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F. Chouaid C, et al. Among authors: waldenberger d. Cancers (Basel). 2022 Dec 13;14(24):6148. doi: 10.3390/cancers14246148. Cancers (Basel). 2022. PMID: 36551632 Free PMC article.
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Griesinger F, Pérol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C. Griesinger F, et al. Among authors: waldenberger d. Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001. Epub 2022 Aug 6. Lung Cancer. 2022. PMID: 36007281 Free article.
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).
Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von der Heyde E, Wiegand J, Ukena D, Bargon J, Schütte W, Riera-Knorrenschild J, Fischer JR, Griesinger F, Allan V, Waldenberger D, Schumann C. Sebastian M, et al. Among authors: waldenberger d. J Immunother. 2022 Feb-Mar 01;45(2):89-99. doi: 10.1097/CJI.0000000000000397. J Immunother. 2022. PMID: 34908007
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M. Debieuvre D, et al. Among authors: waldenberger d. Lung Cancer. 2021 Jul;157:40-47. doi: 10.1016/j.lungcan.2021.04.022. Epub 2021 Apr 30. Lung Cancer. 2021. PMID: 33980420 Free article.